Since the severe acute respiratory syndrome (SARS) outbreak of 2002 and 2003 was recognized, there has been a need to identify appropriate animal models in which pathogenesis and preventive strategies can be evaluated. Several animal species support replication of SARS coronavirus (SARS-CoV) (14, 16, 17, 27, 29, 33) and are useful as models for the evaluation of treatment and prophylaxis against SARS-CoV (1, 4, 5, 12, 30, 34) . However, viral infection found in animal models is accompanied by different degrees of pathology, and reports of associated clinical illness are inconsistent. Although SARSCoV replicates in the respiratory tracts of 4-to 6-week-old BALB/c mice without associated signs of clinical illness or overt pathology (29) , the heightened susceptibility of elderly humans to severe SARS (2, 6, 8, 15, 22, 24, 32) led us to hypothesize that aged mice might be more susceptible to the disease than young mice. We report here a mouse model that demonstrates consistent signs of clinical illness, supports high levels of SARS-CoV replication, and displays histopathological lesions similar to those observed in human cases of SARS (9, 13, 20, 23, 28, 31) .
We administered 10 5 50% tissue culture infective doses (TCID 50 ) of SARS-CoV (Urbani isolate [13] ) intranasally to 12-to 14-month-old BALB/c mice as previously described (29) . SARS-CoV-infected aged mice demonstrated signs of clinical illness characterized by significant weight loss, hunching, ruffled fur, and slight dehydration measured by skin turgor. Weight loss began 3 days postinfection (p.i.), with a nadir of 8% loss on day 4 p.i., and was noted through day 6 (P Ͻ 0.04) (Fig. 1A) . Clinical signs of illness resolved by day 7 p.i., and inactivity, changes in gait, and mortality were not observed.
The levels of viral replication in the lungs, nasal turbinates, liver, and spleen were analyzed from mice that were euthanized (four mice per day) on days 2, 5, 9, and 13 p.i. Supernatants of 10% (wt/vol) tissue homogenates were titrated on Vero cell monolayers as previously described (29) . Virus was detected in lungs at high titers (ϳ10 8 TCID 50 /g) as early as day 2 p.i., and titers remained high (Ͼ10 7 TCID 50 /g) on day 5 p.i. Virus was also recovered from the upper respiratory tract (nasal turbinates) and the liver at days 2 and 5 p.i. (Fig. 1B) . Virus was not detected in whole blood (assayed at 48 and 72 h p.i.; the limit of detection was 10 1.5 TCID 50 /ml) or in spleen.
Following SARS-CoV or mock inoculation, mice were euthanized on days 1, 2, 3, 5, 9, and 13 p.i., and lungs and nasal turbinates were fixed with 10% formalin and processed for histopathological and immunohistochemical (IHC) examination as previously described (13, 17, 28, 29) . Soon after infection (days 1 to 3 p.i.), SARS-CoV antigens were detected by IHC staining in ciliated, columnar epithelial cells of the nasal turbinates and bronchioles ( Fig. 2A and B, respectively) and in alveolar pneumocytes (Fig. 2B) . IHC staining showed SARSCoV antigen associated with epithelial necrosis and abundant necrotic debris in airways ( Fig. 2C to F ). At day 3 p.i., loose collections of mixed perivascular infiltrates comprised predominantly of lymphocytes and histiocytes were noted around vessels adjacent to bronchioles (Fig. 2C ). On day 5 p.i., infected pneumocytes were still detectable ( Fig. 3A ) but in fewer numbers than at day 3 p.i. In contrast, perivascular infiltrates, first noted on day 3 p.i., were more prominent at day 5 p.i. Viral antigens were not detected by IHC staining in respiratory tissues after day 5 p.i. Changes indicative of alveolar damage, including multifocal, interstitial, and predominantly lymphohistiocytic infiltrates, proteinaceous deposits around alveolar walls, and intraalveolar edema, were seen beginning on day 5 p.i. (Fig. 3B ). At day 9 p.i., perivascular infiltrates persisted, and the changes associated with alveolar damage were accompanied by a proliferation of fibroblasts in inflammatory foci (Fig. 3C) . The number and size of these foci decreased over time, but a few persisted in the lungs of some mice for at least 29 days p.i. It is possible that these foci (Fig. 3D ) in SARSCoV-infected mice represent histopathologic correlates of fibrosis or scarring identified by high-resolution computed tomography scanning of the lungs of some human patients who have recovered from severe cases of SARS (7, 19) .
Given the evidence of viral replication and inflammation in the lungs, we examined which inflammatory mediators were present. Aged BALB/c mice were euthanized (four mice per day), and tissues were collected on days 1, 2, 3, 5, 9, and 13 p.i. Supernatants of 20% (wt/vol) lung homogenates were analyzed in duplicate by enzyme-linked immunosorbent assay for the following cytokines per manufacturer protocols: alpha interferon (IFN-␣; PBL Biomedical Laboratories, Piscataway, N.J.), IFN-␥, tumor necrosis factor alpha (TNF-␣), interleukin 4 (IL-4), IL-10, and IL-12 (Quantikine Immunoassays; R&D Systems, Minneapolis, Minn.). Lungs from two mock-infected, age-matched mice were collected for determination of baseline cytokine levels in aged BALB/c mice. Levels of IFN-␣, IFN-␥, and TNF-␣ were elevated (Ͼ2-fold increase over levels in mock-infected control animals) in SARS-CoV-infected aged mice at 2 and 3 days p.i. during peak viral replication (Fig. 4A  to C) . Slight elevations in IFN-␥ and TNF-␣ were also ob- served on day 9 p.i. after the peak of viral replication. However, the other cytokine levels were not elevated greater than twofold over mock levels at any time point assayed (Fig. 4D to  F) . A number of defects in innate and adaptive immune responses have been described to occur during immune senescence in mice and humans (3, 10, 18, 21, 25, 26, 35) . Glass et al. (11) studied the mechanisms underlying the clearance of SARS-CoV from the lungs of young C57BL/6 (B6) mice and inferred that NK cells and adaptive cellular immunity do not play a role in clearance because Beige, CD1
Ϫ/Ϫ , and RAG1
Ϫ/Ϫ mice that selectively lack NK cells, NK-T cells, and T and B lymphocytes, respectively, were able to clear virus as rapidly and completely as normal young B6 (11) and BALB/c (29) mice. Aged BALB/c mice developed mean serum neutralizing SARS-specific antibody titers of 1:14 and 1:38 by 3 and 5 weeks p.i., respectively, which is well within the range of titers seen in young SARS-CoV-infected mice, indicating that aged mice are as capable as young mice of mounting an adaptive immune response to SARS-CoV infection. However, in contrast to young BALB/c and B6 mice, for which elevations in proinflammatory cytokines, clinical illness, and histopathological changes following SARS-CoV infection were not observed (11, 29) , SARS-infected, aged BALB/c mice showed elevated levels of IFN-␣, IFN-␥, and TNF-␣ early in infection. This observation suggests that a proinflammatory cytokine response may be responsible for subsequent disease-associated events. Further exploration of the components of innate and cell-mediated immunity in aged mice, including the presence or absence of various chemokines, is warranted to elucidate the pathogenesis of SARS-associated disease and the mechanism for viral clearance.
In conclusion, we present here the first demonstration of age-related susceptibility to SARS-CoV disease in animals that parallels the human experience with SARS. Replication of SARS-CoV is enhanced and prolonged in 12-to 14-month-old BALB/c mice compared to that in young mice, and the enhanced viral replication is accompanied by evidence of clinical illness, alveolar damage, and interstitial pneumonitis. Elevation of proinflammatory cytokines is also observed in SARSinfected, but not in mock-infected, aged mice. The aged-mouse model will facilitate research into the pathogenesis of SARS and represents a critical addition to the models that are available for SARS prevention and treatment studies.
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